Previous 10 | Next 10 |
Gainers: BriaCell Therapeutics (BCTX) +91%.AMC Entertainment (AMC) +76%.Constellation Pharmaceuticals (CNST) +67%.Bed Bath & Beyond (BBBY) +45%.PetMed Express (PETS) +34%.Urban One (UONE) +31%.Vision Marine Technologies (VMAR) +28%.U.S. Well Services (USWS) +24%.Skillz (SKLZ)...
Do You Have These Top Health Care Stocks On Your June 2021 Watchlist? Given the current state of the stock market now, investors may be turning their attention towards health care stocks. For the most part, this could be because of inflation fears quelling the current momentum i...
BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...
SCYNEXIS (SCYX) announces that the U.S. FDA has approved BREXAFEMME (ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis ((VVC)), also known as vaginal yeast infection.BREXAFEMME was approved based on positive results from two Phase 3 studies in which oral...
Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 years BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp development pipeline ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, investors, and I hope you enjoyed the long weekend! We’re getting right back into the swing of things with a look at the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.co...
Creative Realities (CREX) +34%.Virgin Galactic Holdings (SPCE) +19% after successful weekend space flight.Strongbridge Biopharma (SBBP) +15% after being acquired by Xeris Pharma.Jiuzi Holdings (JZXN) +9%.Aptorum Group Limited (APM) +9% on positive interim phase I clinical trial...
SCYNEXIS (SCYX): Q1 GAAP EPS of -$0.23 beats by $0.35.Cash and cash equivalents totaled $92MPress Release For further details see: SCYNEXIS EPS beats by $0.35
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLs Appointed Christi...
SCYNEXIS ([[SCYX]] +3.2%) secured a $60M term loan facility with Hercules Capital (HTGC) and Silicon Valley Bank for strengthening its balance sheet ahead of the anticipated commercial launch of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate f...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...